Company Insights

MGX customer relationships

Explore interactive graphBrowse insights index
MGX customer relationship map

Metagenomi (MGX) — Collaboration-led revenue, partner concentration, and what investors should know

Metagenomi develops genome-editing therapeutics and monetizes primarily through licensing, option and collaboration agreements with larger biopharma partners that fund R&D and provide potential milestone and royalty upside. The company recognizes revenue when customers obtain control of promised services, and FY2024 filings show material collaboration receipts tied to a small set of large partners, making partner stability central to near-term cash flow and value realization. For an investor-focused breakdown of these commercial relationships, see the Null Exposure homepage: https://nullexposure.com/

How Metagenomi actually earns money — a compact operating thesis

Metagenomi’s operating model is R&D-centric and partner-funded. The firm licenses its metagenomics-derived genome-editing toolbox to strategic collaborators under multi-year research and option arrangements, recording collaboration revenue as those agreements deliver measurable performance obligations. This is a seller posture under ASC 606 (revenue recognized on delivery), with all reported long-lived assets and customer contracts located in the U.S., which concentrates legal and reimbursement exposure to North American healthcare systems. The business is pre-commercial and depends on successful development and commercialization by Metagenomi or its licensees, so partnerships are both the engine of revenue and the primary concentration risk.

Explore deeper partner analytics at Null Exposure: https://nullexposure.com/

Company-level constraints and what they imply for investors

  • Contracting posture — licensing and R&D agreements dominate. The company states its revenue is “primarily derived through its license, research, development and option agreements,” indicating an emphasis on long-term collaborator commitments rather than direct product sales.
  • Geographic concentration — U.S.-centric revenue and assets. All long-lived assets and reported contract revenues relate to U.S. customers, which reduces geopolitical diversification and ties commercial outcomes to U.S. reimbursement and regulatory dynamics.
  • Counterparty profile — large enterprise and government payors matter. Metagenomi recognizes that sales and adoption depend on coverage by third-party payors including government health programs and commercial insurers, signaling payer exposure once products approach commercialization.
  • Role and maturity — seller of R&D/collaboration services; pre-commercial risk persists. The company functions as a seller of research and development services/licensing today, and must successfully develop therapies (or rely on collaborators) to reach profitability.

Partner-by-partner read — every relationship in the public results

Affini-T (10-K, FY2024)

Metagenomi’s FY2024 Form 10‑K lists collaboration revenue attributed to “Affini-T” totaling 3,114 in the period reported, indicating an active commercial research/license flow recorded in annual statements. According to the FY2024 Form 10‑K (mgx-2024-12-31), Affini‑T contributed collaboration revenue for the year.

Ionis Pharmaceuticals, Inc. (news profile, FY2026)

The company has a collaboration and license agreement with Ionis to research, develop and commercialize investigational medicines using genome editing technologies, positioning Ionis as a strategic scientific and commercial partner. This relationship is described in a SimplyWallStreet company profile summarizing Metagenomi (news; FY2026).

Moderna, Inc. — partnership termination reported (Biospace, FY2025)

Moderna terminated its gene-editing partnership with Metagenomi in 2025, a move that eliminated a program that had carried up to $3 billion in potential contingent payments, leaving Metagenomi with rights to a preclinical program. Biospace’s coverage of workforce reductions and program focus (news; FY2025) reports Moderna’s withdrawal.

Affini-T Therapeutics, Inc. — development, option and license deal (SimplyWall, FY2026)

A SimplyWallStreet summary notes a development, option and license agreement with Affini‑T Therapeutics to develop and commercialize TCR-based, gene-edited therapeutics exclusively for oncology, confirming the strategic nature of the Affini‑T relationship beyond one-time payments (news; FY2026).

Ionis (10-K, FY2024)

Metagenomi’s FY2024 Form 10‑K records collaboration revenue associated with “Ionis” of 30,439 for the period, highlighting Ionis as a major revenue source in the company’s reported accounts. The FY2024 Form 10‑K (mgx-2024-12-31) shows Ionis-contributed collaboration revenue for the fiscal year.

Ionis Pharmaceuticals (FierceBiotech coverage, FY2025)

FierceBiotech reports Metagenomi is continuing cardiometabolic work under a $3 billion biobucks collaboration with Ionis, underscoring the scale and continued strategic priority of Ionis-linked programs in Metagenomi’s pipeline (news; FY2025).

Moderna — litigation and disclosure questions (GlobeNewsWire, FY2024)

A November 2024 press release about a securities lawsuit alleges misrepresentations regarding the company’s collaboration with Moderna under a Strategic Collaboration and License Agreement entered October 29, 2021, showing how the Moderna relationship has become a governance and disclosure focus in investor communications (GlobeNewsWire release; FY2024).

Moderna (10-K, FY2024)

The FY2024 Form 10‑K lists collaboration revenue attributed to “Moderna” of 18,742 for the period, confirming Moderna was a material collaborator in reported revenues before the later termination. See Metagenomi’s FY2024 Form 10‑K (mgx-2024-12-31).

Moderna (FierceBiotech follow-up, FY2025)

FierceBiotech again notes Moderna’s exit from its $3 billion “biobucks” collaboration, leaving Metagenomi with rights to a specific preclinical program (news; FY2025), reinforcing the strategic and financial impact of the Moderna termination on the company’s near-term outlook.

What investors should take away — risks, concentration, and upside

  • Concentration risk is material. A small set of large collaborators (Ionis, Moderna, Affini‑T) account for the bulk of reported collaboration revenue; FY2024 10‑K line items show Ionis and Moderna as large revenue contributors. That concentration creates asymmetric downside if a partner departs, as Moderna’s exit demonstrated.
  • Business model is partner-dependent licensing. The company’s posture is licensing-heavy and reliant on collaborators to advance and commercialize assets; revenue recognition follows delivery of research/license obligations rather than product sales.
  • Regulatory, payer and geographic exposure is concentrated in the U.S. All long-lived assets and contract revenues are U.S.-based, so reimbursement and coverage dynamics will be decisive when programs near market.
  • Operational maturity is early-stage. Metagenomi is pre-commercial with negative operating margins; strategic execution and partner stability drive the path to profitability and any realized royalties or milestone payments.

For investors and operators wanting more structured partner exposure and revenue-trend analysis, visit Null Exposure for expanded partner intelligence and primary-document visibility: https://nullexposure.com/

Metagenomi’s valuation and near-term cash profile are driven more by the durability and scope of these collaborations than by product sales—the company is a platform monetized through a handful of large licensing relationships, and that structure defines both its upside and its headline risks.